Muhammet Bekir HACIOĞLU, Mustafa ERGİN, Fatih KARATAŞ, Gökşen İMAMOĞLU İNANÇ, Aydın AYTEKİN, Rüçhan AÇIKGÖZ, Mustafa ALTINBAŞ, Süleyman ŞAHİN

Mikst Primer Prostat Adenokanseri ve Nöroendokrin Diferansiyasyonla Gelişen Prostat Küçük Hücreli Kanseri-Olgu Sunumu

Küçük hücreli prostat kanseri nadir görülen bir kanser tipidir ve tüm prostat kanserleri içerisinde %1den daha azınıoluşturur. Küçük hücreli prostat kanseri klasik adenokanserden klinik ve histolojik olarak farklı özelliklere sahiptir.Blastik kemik metazsazlarına oranla litik kemik metastazı yapma eğiliminde olup labaratuvar olarak da normalyada çok az artmış PSA seviyeleriyle karşımıza çıkmaktadır. Literatürde vaka sayısının az olması nedeniyle ortalamasağkalım süresi hakkında sınırlı bilgi mevcuttur. Hormonoterapiye dirençlidir ve günümüzde küçük hücreli akciğerkanserine benzer tedavi rejimleri ile tedavi edilmektedir. Platin temelli kemoterapi ile başlangıçta iyi bir cevap alın- masına rağmen, tedavi efektif olmamaktadır. Hastalığın prognozu oldukça kötü olup tanı anında ilerlemiş hastalıkevresindedir. Ortalama yaşam süresi tanıdan itibaren 2 yıldan kısadır. Burada, prostat adenokanser nedeniyle hormonoterapi alan hastada nöroendokrin differansiasyon ile küçük hücreli prostat kanseri gelişmesi literatür bilgilerieşliğinde bahsedilecektir.

Mixed Primary Prostate Adenocarcinoma and Prostate Small Cell Carcinoma Deriving From Neuroendocrine Differentiation - a case report

Prostate small cell carcinoma is a rare malignancy and accounts for less than %1 of all prostatic carcinomas. It sepa- rates with lots of clinical and histological features from classic adenocarcinoma. Contrary to adenocarcinoma , smallcell carcinoma is found to have lytic bone metastasis and serum PSA level is within normal range or increased onlya little quantity. Due to limited number of case reports in literature, there is a little information about median survivaltime. It is hormone-resistant and treatment regimen is found to be similar to small cell lung cancer. In spite of goodresponse at initial, platinum-based chemotherapy is not an effective treatment. Prognosis is rather poor and most ofthe patients have advanced stage at the time of the diagnosis. Median survival time is less than 2 years from followinginitial diagnosis. Herein, we reported small cell carcinoma derived from neuroendocrine differentiation in a patientwho was priorly treated with hormone therapy for prostate adenocarcinoma, in the light of the literature.

PDF

___

1. SiegelR, NaishadhamD, JemalA. Cancer statistics. CA Cancer J Clin 2013;63:1130.doi:10.3322/caac.21166
2. F Abbas, F Civantos, P Benedetto and MS Soloway. Small cell carcinoma of the bladder and prostate. Urology vol. 46, no.5, pp. 617630, 1995
3. Wang W, Epstein JI. Small cell carcinoma of the prostate: A morphologic and Immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32:65-71.
4. Tanaka M, Suzuki Y, Takaoka K, Suzuki N, Murakami S, Matsuzaki O, et al. Progresion of prostat cancer to neuroendocrine cell tumor. Int j urol 2001;8:431-6.
5. Rubenstein JH, Katin MJ, Mangano MM, Dauphin J, Salenius SA, Dosoretz DE, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the litherature and discussion of a therapeutic strategy. Am J Clin Onc. 1997;20:376-380.
6. Mosca A, et al. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest. 2005; 28(11 Suppl International): 141-5.
7. di SantAgnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol. 1992; 23:287-96.
8. di SantAgnese P. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992;70254-68.
9. .di SantAgnese P. Neuroendocrine differentiation in prosratic carcinoma. Recent findings and new concepts. Cancer 1995;75:1850-59.
10. Abrahamsson PA.Neuroendocrine differantiation in prostatic carcinoma a. Prostate. 1999;39:135-48
11. Petraki C, Vaslamatsiz M, Petraki K, Revelos K, Alevizopoulos N, Papanastasiou P, et al. Prostate cancer with small cell morphology: An immunophenotypic subdivision. Scan J urol Nephrol. 2005;39 :455-63.
12. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S, et al. Small cell carcinoma of the prostate: An immunohistochemical study. Am J surg Pathol.2006;30:705-12.
13. Tetu B, JY Ro and AG Ayala. Small cell carcinoma of the prostate Part I. A clinicopathologic study of 20 cases. Cancer vol. 59, no. 10, pp. 18031809, 1987.
14. JE Oesterling, CG Hauzeur and GM Farrow. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. Journal of Urology. vol. 147, no. 3, pp. 804807, 1992.
15. RE Wenk, BS Bhagavan and R Levy. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer, vol. 40, no. 2, pp. 773778, 1977.
16. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997 ;50:754-8.
17. Papandeou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of phase II study with doxorubicin,etoposid and cisplatin in patients with fully charecterized small cell carcinoma of the prostate. J Clin On 2002;20:3072-80.
18. HS Coskun, O Er, M. Altınbas, E Karahacıoglu and B Eser. Ekstrapulmoner kucuk hucreli kanser: tedavi ve prognoz. Turk Onkoloji Dergisi vol. 16, pp. 191193, 2001.